SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout

Wilmington, Delaware, UNITED STATES

WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches of fiduciary duties and other violations of law related to Prevail’s agreement to be acquired by Eli Lilly and Company (NYSE: LLY).   Under the terms of the agreement, Prevail’s shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.

To learn more about this investigation and your rights, visit:

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530